



## Phage Therapy to Control Pathogenic Bacteria, 2nd Edition

Guest Editors:

### Dr. Carla Pereira

Department of Biology and  
CESAM, University of Aveiro,  
Campus Universitário de  
Santiago, 3810-193 Aveiro,  
Portugal

### Prof. Dr. Adelaide Almeida

Departamento de Biologia,  
CESAM - Centro de Estudos do  
Ambiente e do Mar, Campus  
Universitário de Santiago,  
Universidade de Aveiro, 3810-193  
Aveiro, Portugal

Deadline for manuscript  
submissions:

**closed (30 September 2022)**

### Message from the Guest Editors

Dear Colleagues,

The first volume of the Special Issue “Phage Therapy to Control Pathogenic Bacteria” was published in 2021. It is a successful Issue with nine published papers and has encouraged us to open a second volume with the same topic.

As a continuation of the Special Issue published in 2021, this second volume will also deliver an invaluable compendium of the latest approaches and challenges associated with the development of phage therapy. Topics may include but are not limited to recent advances in bacteriophage research for bacterial disease control in different areas (veterinary medicine, food industry, agriculture, aquaculture, and human medicine).

**Keywords:** bacteriophages; bacteriophage therapy; human infections; animal infections; plant infections; phage pharmacokinetics; combination therapies; biofilm control; phage resistance





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi